37.41 +0.27 (0.72%)
SNY
| Trade SNY now with |
|
Stock Details
Last Trade:37.41 Change:+0.27 (0.72%) Prev Close:37.14 Open: 37.54 Days Range:37.11 – 37.54 52 Week Range: 30.98 - 40.75 Volume:2810634 P/E: N/AEPS:0.00
View AllRecent Alerts 02/09/12
Recent Alert on 02/08/12 at 11:04am
Sanofi's (SNY) Genzyme Reports Continued Endpoint Improvement for Eliglustat Tartrate in Phase 2 Trials
Sanofi's (SNY) Genzyme Reports Continued Endpoint Improvement for Eliglustat Tartrate in Phase 2 Trials
Genzyme, a Sanofi company (NYSE: SNY), announced today four-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further... Read More
Recent Alert on 02/08/12 at 11:04am
Sanofi's (SNY) Genzyme Reports Continued Endpoint Improvement for Eliglustat Tartrate in Phase 2 Trials
Sanofi's (SNY) Genzyme Reports Continued Endpoint Improvement for Eliglustat Tartrate in Phase 2 Trials
Recent Alert on 02/08/12 at 6:52am
Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement
Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement
Recent Alert on 02/08/12 at 6:52am
Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement
Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement
Recent Alert on 02/08/12 at 6:52am
Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement
Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement
View AllRecent Press Releases
Press Release on 02/08/12 at 11:00am
Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints
Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints
Press Release on 02/08/12 at 1:30am
Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex
Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex
Press Release on 02/07/12 at 2:04pm
Sanofi Announces FDA Approval of Sklice® Lotion for the Treatment of Head Lice
Sanofi Announces FDA Approval of Sklice® Lotion for the Treatment of Head Lice
View AllRecent SEC Filings
View AllRecent Blog Posts
Blog Posts on 02/08/12 at 2:40pm
Portfolio Playoffs -- Finding The Best Dividend Portfolio (Part ll)
Portfolio Playoffs -- Finding The Best Dividend Portfolio (Part ll)